Cahill Represents Dyadic International in Sale of Industrial Technology Business to DuPont Industrial Biosciences
Date: 12/31/15
Cahill represented Dyadic International, Inc., a global biotechnology company, in connection with the sale of substantially all of the assets of its Industrial Technology business, including its C1 platform, a technology for producing enzyme products used in a broad range of industries, to DuPont Industrial Biosciences for $75 million in cash. In connection with the transaction, DuPont granted back to Dyadic co-exclusive rights to the C1 technology for use in human and animal pharmaceutical applications.